IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

被引:375
作者
Bronte, V
Serafini, P
De Santo, C
Marigo, I
Tosello, V
Mazzoni, A
Segal, DM
Staib, C
Lowel, M
Sutter, G
Colombo, MP
Zanovello, P
机构
[1] Univ Padua, Dept Oncol & Surg Sci, Oncol Sect, I-35128 Padua, Italy
[2] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
[3] GSF Munich, Natl Res Ctr Environm & Hlth, Inst Mol Virol, Munich, Germany
[4] Ist Nazl Tumori, Dept Expt Oncol, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy
关键词
D O I
10.4049/jimmunol.170.1.270
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We previously demonstrated that a specialized subset of immature myeloid cells migrate to lymphoid organs as a result of tumor growth or immune stress, where they suppress B and T cell responses to Ags. Although NO was required for suppression of mitogen activation of T cells by myeloid suppressor cells (MSC), it was not required for suppression of allogenic responses. In this study, we describe a novel mechanism used by MSC to block T cell proliferation and CTL generation in response to alloantigen, which is mediated by the enzyme arginase 1 (Arg1). We show that Arg1 increases superoxide production in myeloid cells through a pathway that likely utilizes the reductase domain of inducible NO synthase (iNOS), and that superoxide is required for Arg1-dependent suppression of T cell function. Arg1 is induced by IL-4 in freshly isolated MSC or cloned MSC lines, and is therefore up-regulated by activated Th2, but not Th1, cells. In contrast, iNOS is induced by IFN-gamma and Th1 cells. Because Arg1 and iNOS share L-arginine as a common substrate, our results indicate that L-arginine metabolism in myeloid cells is a potential target for selective intervention in reversing myeloid-induced dysfunction in tumor-bearing hosts.
引用
收藏
页码:270 / 278
页数:9
相关论文
共 38 条
[1]   ROLE OF ORNITHINE AS A PROLINE PRECURSOR IN HEALING WOUNDS [J].
ALBINA, JE ;
ABATE, JA ;
MASTROFRANCESCO, B .
JOURNAL OF SURGICAL RESEARCH, 1993, 55 (01) :97-102
[2]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[3]  
Angulo I, 2000, EUR J IMMUNOL, V30, P1263, DOI 10.1002/(SICI)1521-4141(200005)30:5<1263::AID-IMMU1263>3.0.CO
[4]  
2-5
[5]   Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes [J].
Apolloni, E ;
Bronte, V ;
Mazzoni, A ;
Serafini, P ;
Cabrelle, A ;
Segal, DM ;
Young, HA ;
Zanovello, P .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :6723-6730
[6]  
Bingisser RM, 1998, J IMMUNOL, V160, P5729
[7]   Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization [J].
Boucher, JL ;
Moali, C ;
Tenu, JP .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (8-9) :1015-1028
[8]   N-OMEGA-HYDROXY-L-ARGININE, AN INTERMEDIATE IN THE L-ARGININE TO NITRIC-OXIDE PATHWAY, IS A STRONG INHIBITOR OF LIVER AND MACROPHAGE ARGINASE [J].
BOUCHER, JL ;
CUSTOT, J ;
VADON, S ;
DELAFORGE, M ;
LEPOIVRE, M ;
TENU, JP ;
YAPO, A ;
MANSUY, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 203 (03) :1614-1621
[9]  
Brito C, 1999, J IMMUNOL, V162, P3356
[10]   Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells [J].
Bronte, V ;
Apolloni, E ;
Cabrelle, A ;
Ronca, R ;
Serafini, P ;
Zamboni, P ;
Restifo, NP ;
Zanovello, P .
BLOOD, 2000, 96 (12) :3838-3846